Loading
A Danish randomised trial in which a urine RNA test was used to decide when people under bladder cancer follow-up needed a camera examination of the bladder.
1,029 cystoscopies were performed in the control arm and 445 in the intervention arm. The risk difference for high-grade recurrence was 0.08 per cent (95% CI minus 7.2 to 7.4), and two pTa high-grade recurrences were missed.
A urine RNA test cut camera examinations by more than half in this trial, with two missed recurrences.
Shares Xpert Bladder Cancer Monitor, Urine tests for bladder cancer (cytology, FISH, RNA and methylation), Liquid RNA biopsy (cell-free, vesicle and platelet RNA), Biomarker.
Shares Liquid RNA biopsy (cell-free, vesicle and platelet RNA), Biomarker.
Shares Liquid RNA biopsy (cell-free, vesicle and platelet RNA), Biomarker.
Shares Liquid RNA biopsy (cell-free, vesicle and platelet RNA), Biomarker.
Shares Liquid RNA biopsy (cell-free, vesicle and platelet RNA), Biomarker.
Shares Liquid RNA biopsy (cell-free, vesicle and platelet RNA), Biomarker.
Shares Liquid RNA biopsy (cell-free, vesicle and platelet RNA), Biomarker.
Shares Liquid RNA biopsy (cell-free, vesicle and platelet RNA), Biomarker.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/